Survival Trends and Prognostic Modeling in ALK-Positive Anaplastic Large Cell Lymphoma: A Population-Based Study in the Brentuximab Vedotin Era. | Synapse
March 8, 2026
Survival Trends and Prognostic Modeling in ALK-Positive Anaplastic Large Cell Lymphoma: A Population-Based Study in the Brentuximab Vedotin Era.
Key Points
This research aims to evaluate survival trends and develop prognostic models for ALK-positive anaplastic large cell lymphoma (ALCL).
Analyzed population-based survival data for ALK+ ALCL patients.
Assessed the impact of brentuximab vedotin (BV) on survival outcomes.
Utilized a risk stratification model (RSF) for prognostic analysis.
Real-world survival rates improved significantly with the introduction of batentuximab vedotin.
The RSF model effectively stratified patients based on individualized risk for better prognostic insight.
Abstract
The introduction of BV has significantly improved real-world survival in ALK+ ALCL. The RSF model enables individualized risk stratification and may support future precision treatment strategies.